Company intelligence / Profile preview

Saffron Therapeutics

Cleveland, Ohio, United States

Ownership: Private
Development stage: Other

Overview

Saffron Therapeutics was a clinical-stage biotechnology company focused on developing gene therapies for rare lysosomal storage disorders affecting the central nervous system. The company's primary assets included AAV-based gene therapy programs for Sanfilippo syndrome types A and B, which were licensed from Nationwide Children's Hospital. In 2016, Saffron was acquired by Abeona Therapeutics, which integrated these programs into its rare disease pipeline. The lead programs, now known as ABO-102 and ABO-101, represent significant advancements in treating pediatric neurodegenerative diseases.

Therapeutic areas: Rare Diseases
Modalities: Gene therapyAdeno-associated virus vector
Industry: Biotech

Partnerships

Nationwide Children's Hospital

Beyond the preview

Go deeper on Saffron Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saffron Therapeutics.

Explore the full profile